Following ACR Convergence 2020 we speak with Peter C Taylor (University of Oxford, Oxford, UK) about his highlights from the meeting.
Part 1 in the series covers the SEAM-RA study designed to investigate the effect of therapy reduction in RA patients with persistent submission receiving a combination of methotrexate and etanercept.
The abstract entitled ‘Maintenance of Remission After Withdrawal of Etanercept or Methotrexate in Patients with Rheumatoid Arthritis in Sustained Remission on Combination Therapy: Results from a Randomized, Double-blind, Controlled Trial’ was presented at ACR Convergence 2020.
Other highlights in this series include PART 2, PART 3 and PART 4.
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
